ADVFN ADVFN

Hot Features

Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
Bristol Myers Squibb

Bristol Myers Squibb (BRM)

48,16
-0,05
( -0,10% )
Mis à jour : 11:22:32

Bristol Myers Squibb (BRM) Action

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Statistiques et détails clés

Dernier
48,16
( -0,10% )
Prix Achat
48,16
Prix Vente
48,54
Volume échangé
722
48,14 Fourchette du Jour 48,55
36,20 Plage de 52 semaines 53,71
Cap du marché
Clôture Veille
48,21
Ouverture
48,44
Dernière Transaction
5
@
48.16
Dernière heure de transaction
11:22:32
Volume financier
-
VWAP
-
Volume moyen (3 m)
11 510 595 €
Actions en circulation
2 042 071 247
Rendement du Dividende (LTM)
2,5 (4,24%)
Ratio Cours sur Bénéfices
16,04
Bénéfice par action (BPA)
3,57
Chiffre d'affairess (LTM)
48,48B
Bénéfice net (LTM)
7,28B

À propos de Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience. The company’s products include Opdivo for various anti-cancer indicat... Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience. The company’s products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag for the treatment of unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM. It also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for a reduction in risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane for the treatment of breast cancer. Further, it provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; and NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. Bristol-Myers Squibb Company has a strategic collaboration with Arcus Biosciences, Inc. to develop a novel treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey. Show more

Secteur
Healthcare
Industrie
Pharmaceuticals
Site Web
Siège social
Princeton, United States
Fondé
1887
Bristol Myers Squibb est coté dans le secteur Healthcare de la Tradegate (DE) avec le ticker BRM. Le dernier cours de clôture d'Bristol Myers Squibb était de 48,21 €. Au cours de la dernière année, les actions de Bristol Myers Squibb ont été négociées dans une fourchette de prix de 36,20 € à 53,71 €.

Bristol Myers Squibb compte actuellement 2 042 071 247 actions en circulation. La capitalisation boursière d'Bristol Myers Squibb est de 98,35 € milliard. Bristol Myers Squibb a un ratio cours/bénéfice (ratio PE) de 16.04.

BRM Dernières nouvelles

Aucune actualité à afficher pour le moment.
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10.9151.9367128796747.24550.246.575399348.09361193DE
40.8251.7428963768947.33551.7146.575368148.92758425DE
12-4.14-7.9158699808852.353.546.575423449.86164447DE
263.9558.946951702344.20553.7143.12608748.9068917DE
525.86000113.853430587642.29999953.7136.2891342.83808235DE
156-12.34-20.396694214960.56136.2819444.93549606DE
260-3.84-7.384615384625280.536.2567747.18739769DE

BRM - Frequently Asked Questions (FAQ)

What is the current Bristol Myers Squibb share price?
The current share price of Bristol Myers Squibb is 48,16 €
How many Bristol Myers Squibb shares are in issue?
Bristol Myers Squibb has 2 042 071 247 shares in issue
What is the market cap of Bristol Myers Squibb?
The market capitalisation of Bristol Myers Squibb is EUR 98,35B
What is the 1 year trading range for Bristol Myers Squibb share price?
Bristol Myers Squibb has traded in the range of 36,20 € to 53,71 € during the past year
What is the PE ratio of Bristol Myers Squibb?
The price to earnings ratio of Bristol Myers Squibb is 16,04
What is the cash to sales ratio of Bristol Myers Squibb?
The cash to sales ratio of Bristol Myers Squibb is 2,41
What is the registered address of Bristol Myers Squibb?
The registered address for Bristol Myers Squibb is Route 206 & Province Line Road, Princeton, New Jersey, 08543
What is the Bristol Myers Squibb website address?
The website address for Bristol Myers Squibb is www.bms.com
Which industry sector does Bristol Myers Squibb operate in?
Bristol Myers Squibb operates in the Pharmaceuticals sector

BRM Transactions

Plus

Transactions différées

Pour obtenir des transactions en temps réel, améliorez votre compte

Passer à la version en temps réel
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock